Overview

The Revised International Prognostic Scoring System (IPSS-R) is the most widely validated and clinically adopted prognostic instrument for Myelodysplastic Syndromes (MDS). Published in 2012 by Greenberg et al. in Blood, the IPSS-R was developed by re-analysing the original 816-patient IPSS cohort alongside seven additional international databases, yielding a combined dataset of 7,012 untreated primary MDS patients. This substantially larger derivation cohort enabled finer cytogenetic sub-classification, continuous modelling of individual variables, and a five-tier risk stratification that replaced the four tiers of its predecessor.

The IPSS-R assigns weighted points across five independent prognostic variables: cytogenetic risk group, bone marrow blast percentage, hemoglobin, platelet count, and absolute neutrophil count (ANC). The resulting total score places patients into one of five risk categories (Very Low, Low, Intermediate, High, and Very High), each associated with a distinct median overall survival and a median time to 25% cumulative incidence of AML transformation. These outcome benchmarks directly inform the urgency and intensity of treatment decisions, from watchful waiting and supportive care in lower-risk disease to prompt initiation of hypomethylating agents and allogeneic stem cell transplantation in higher-risk disease.

Myelodysplastic Syndromes: A Clinician’s Framework

MDS is a heterogeneous group of clonal hematopoietic stem cell disorders characterised by ineffective hematopoiesis, peripheral cytopenias, and morphological dysplasia in one or more myeloid lineages. The clinical presentation ranges from an incidentally discovered mild anemia in an otherwise asymptomatic older adult to severe pancytopenia with transfusion dependency, bleeding, recurrent infections, and rapid progression to acute myeloid leukemia (AML).

The incidence of MDS rises steeply with age, with a median age at diagnosis of approximately 70 years in most Western registries. The estimated annual incidence is 3 to 5 cases per 100,000 population, rising to more than 30 per 100,000 in those aged 70 years and older. MDS is the most common myeloid malignancy in adults and the most frequent indication for non-transplant disease-modifying therapy in hematology. Underlying genetic events include somatic mutations in genes regulating RNA splicing (SF3B1, SRSF2, U2AF1), epigenetic regulation (TET2, DNMT3A, ASXL1, EZH2), transcription (RUNX1), and signal transduction (NRAS, CBL), in addition to chromosomal abnormalities captured by the IPSS-R cytogenetic grouping.

The WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th edition, 2022) subclassifies MDS by morphological features (dysplastic lineages, ring sideroblasts, fibrosis), blast percentage, and specific genetic lesions. However, WHO subtype alone does not fully capture prognosis, which is why the IPSS-R remains indispensable in clinical practice as a quantitative tool that transcends individual morphological categories and provides patient-specific outcome estimates directly actionable at the point of care.

Historical Context: From IPSS to IPSS-R

The original International Prognostic Scoring System (IPSS), published by Greenberg et al. in 1997, was the first rigorously validated prognostic model for MDS. It incorporated three domains: percentage of bone marrow blasts, number of cytopenias, and cytogenetic risk (grouped into three categories: good, intermediate, and poor). The IPSS generated four risk categories (Low, INT-1, INT-2, and High) and became the global standard for both clinical practice and clinical trial eligibility stratification for more than a decade.

Despite its longevity, the IPSS had recognised limitations. The three-group cytogenetic classification collapsed a biologically diverse set of karyotypic abnormalities into broad groups with overlapping prognoses. Cytopenias were treated as a count rather than as individual continuous variables, obscuring the differential prognostic weights of anemia, thrombocytopenia, and neutropenia. The four-tier risk grouping also failed to adequately separate the most indolent cases (now IPSS-R Very Low) from the intermediate-risk group with which they were previously co-classified.

The IPSS-R addressed each of these limitations. Cytogenetics were expanded to five groups derived from analysis of 19 distinct karyotypic lesions. Hemoglobin, platelet count, and ANC were modelled as independent continuous variables with individually optimised cut-points and weighting. The five resulting risk categories provided meaningfully distinct survival and transformation rate estimates, and the Intermediate category was maintained as a genuinely transitional zone requiring individualised treatment decisions rather than a default low-risk bin.

The Five Prognostic Variables

1. Cytogenetic Risk Group

Cytogenetics is both the highest-weighted and most informationally rich variable in the IPSS-R, contributing 0 to 4 points. Its dominant prognostic weight reflects the fact that chromosomal abnormalities are direct markers of clonal genomic instability, often capturing the functional consequence of accumulated somatic mutations on cellular architecture.

The five cytogenetic risk groups and their associated point values are:

The Very Good group (0 points) encompasses loss of Y chromosome in males, which in isolation is often considered a normal finding in older men and has a prognostic profile indistinguishable from normal karyotype in most series, and del(11q), which is uncommon but associated with favourable outcomes. These cases have median survival approaching or exceeding that of age-matched controls in some reports.

The Good group (1 point) includes normal karyotype, which constitutes the majority of MDS cases. Del(5q) as an isolated finding or combined with one additional favourable abnormality defines a biologically and clinically distinct MDS subtype (MDS with del(5q)) with characteristic morphology, erythroid-predominant transfusion dependency, and selective responsiveness to lenalidomide. Del(12p) and del(20q) are individually uncommon but associated with favourable cytogenetic biology.

The Intermediate group (2 points) captures a biologically heterogeneous set of abnormalities including trisomy 8 (+8, the single most common numeric chromosomal change in MDS), del(7q) (distinct from monosomy 7 in prognosis), trisomy 19 (+19), and isochromosome 17q. This group also includes single and double abnormalities that do not fit a more specific category, reflecting the limit of grouping in the face of karyotypic diversity.

The Poor group (3 points) includes monosomy 7 (−7), one of the most adverse cytogenetic events in MDS and associated with accelerated progression to AML; inv(3)/t(3q)/del(3q) abnormalities, which involve the MECOM locus and confer particularly poor prognosis; and the presence of exactly three chromosomal abnormalities (complex karyotype, 3-hit).

The Very Poor group (4 points), i.e. complex karyotype with more than three abnormalities, is associated with the shortest median survival and highest AML transformation rates. Genomically, these cases tend to harbour global chromosomal instability and frequently overlap with TP53 mutations, which are strongly associated with complex cytogenetics and confer independent adverse prognosis beyond the IPSS-R score.

Cytogenetic assessment in MDS requires conventional metaphase karyotyping from bone marrow aspirate. At least 20 metaphases should be analysed for adequate sensitivity. Fluorescence in situ hybridisation (FISH) is a useful adjunct when metaphase cytogenetics fails or yields insufficient metaphases, but cannot replace the global karyotypic overview provided by conventional banding. Molecular cytogenomic approaches (chromosomal microarray, optical genome mapping) are increasingly used in specialist centres and can detect cryptic deletions and amplifications not visible on conventional karyotype, though their integration into IPSS-R scoring has not been formally validated.

2. Bone Marrow Blast Percentage

The bone marrow blast percentage is the most direct measure of disease advancement along the MDS to AML transformation continuum and contributes 0 to 3 points. By convention, blasts are expressed as a percentage of all nucleated cells on a 200 to 500 cell differential count from the bone marrow aspirate smear.

The IPSS-R upper limit for MDS classification is 19% blasts; cases with 20% or more blasts meet the WHO definition of AML and are excluded from MDS prognostic scoring. However, the original IPSS-R dataset included some patients with blast percentages in the 10 to 19% range, and the 3-point ceiling at >10% reflects the high-risk contribution of this group within the MDS diagnostic boundary.

Blast counting in MDS is subject to inter-observer variability, particularly in the hypocellular marrow that characterises some MDS subtypes, in samples with poor morphological preservation, and in cases where dysplastic blast-like cells are difficult to distinguish from early myeloid precursors. Immunophenotyping by multiparameter flow cytometry and immunohistochemistry (CD34 staining on trephine biopsy) can improve blast enumeration accuracy and should be used when aspirate smear quality is suboptimal.

The biological significance of each blast tier reflects the progressive displacement of normal haemopoiesis by the expanded abnormal clone. Even the >2% to <5% tier carries meaningful additional risk compared with ≤2%, justifying its independent contribution to the score. Blast percentage is also dynamic: repeat bone marrow assessment is recommended at relapse, loss of response to therapy, or significant clinical deterioration, as blast progression is a critical trigger for treatment escalation.

3. Hemoglobin

Anemia is the most common and frequently the most symptomatic cytopenia in MDS, present in 80 to 90% of patients at diagnosis. Hemoglobin contributes 0 to 1.5 points in the IPSS-R, with the half-point allocation at the <8 g/dL threshold reflecting the disproportionate morbidity and mortality associated with severe anemia:

The MDS-related anemia is primarily dyserythropoietic in origin: morphologically dysplastic erythroid precursors undergo apoptosis within the bone marrow before completing maturation, resulting in ineffective erythropoiesis despite often-hypercellular marrow. This is compounded in some cases by elevated endogenous erythropoietin resistance, iron sequestration in macrophages, and the chronic inflammatory milieu of the clonal marrow environment.

Chronic severe anemia (hemoglobin <8 g/dL) in the IPSS-R context drives transfusion dependency, which carries its own adverse prognostic implications: each unit of packed red blood cells delivers approximately 200 to 250 mg of iron, and over time, repeated transfusions lead to iron overload in the heart, liver, and endocrine glands. Transfusion- dependent patients with MDS have consistently worse outcomes than transfusion-independent patients matched for IPSS-R score, prompting debate about whether transfusion burden should be formally incorporated into future scoring revisions.

Clinically, the hemoglobin value used for IPSS-R scoring should reflect the patient’s steady-state count, not a post-transfusion nadir. Where a patient has recently received transfusions, the pre-transfusion hemoglobin or a value obtained after sufficient time for equilibration provides a more accurate representation of endogenous erythropoietic capacity.

4. Platelet Count

Thrombocytopenia in MDS reflects dysmegakaryopoiesis and occurs in approximately 40 to 60% of patients at diagnosis. Platelet count contributes 0 to 1 point:

Severe thrombocytopenia (<50 ×10⁹/L) is associated with clinically significant bleeding risk, particularly mucosal haemorrhage, gastrointestinal bleeding, and intracerebral haemorrhage. In practice, the threshold for prophylactic platelet transfusion in haematologically stable MDS patients without other bleeding risk factors is typically 10 to 20 ×10⁹/L, rising to higher thresholds during invasive procedures, active bleeding, or hypomethylating agent administration.

MDS-related thrombocytopenia also has qualitative dimensions: platelet function may be impaired due to dysplastic megakaryocyte cytoplasmic defects even at counts above the conventional bleeding threshold. Acquired von Willebrand disease occasionally coexists in MDS and may contribute to bleeding disproportionate to the platelet count.

5. Absolute Neutrophil Count (ANC)

Neutropenia in MDS arises from dysmyelopoiesis and is present in approximately 50 to 60% of patients to some degree, though severe neutropenia (ANC <0.5 ×10⁹/L) is less common at presentation than anemia or thrombocytopenia. ANC contributes 0 to 0.5 points:

The relatively modest weight of ANC in the IPSS-R compared to cytogenetics and blast percentage reflects the fact that neutropenia’s independent prognostic contribution to overall survival and AML transformation is partially mediated through its co-occurrence with higher-risk disease features. Nonetheless, an ANC below 0.8 ×10⁹/L is a clinically meaningful threshold: patients in this range are at increased risk of recurrent bacterial and fungal infections, which in the setting of a dysfunctional immune marrow microenvironment may be both more severe and more difficult to clear than in other neutropenic settings.

The functional quality of MDS neutrophils is also impaired: dysgranulopoiesis results in neutrophils with abnormal granulation, hypersegmented or hyposegmented nuclei (the pseudo-Pelger-Huët anomaly), and deficient oxidative burst and phagocytic capacity. Infectious morbidity in MDS therefore occurs across a broader ANC spectrum than in chemotherapy-induced neutropenia, where functional neutropenia is less prominent above 1.0 ×10⁹/L.

IPSS-R Score Calculation

The total IPSS-R score is the arithmetic sum of the five variable subscores. The possible range is 0 to 10, though in practice extreme scores at both ends are uncommon. The five risk categories and their threshold score ranges are:

The outcome data above are derived from the original derivation cohort of untreated primary MDS patients. They represent statistical medians: half of patients in each category survived longer than the stated median, and half a shorter time. Individual patient outcomes vary substantially based on patient age, comorbidities, treatment received, and molecular genetics not captured by IPSS-R. Accordingly, these figures should be communicated as population-level benchmarks rather than individual prognoses.

The use of the 25% AML cumulative incidence (rather than 50% or median) as the transformation endpoint reflects the competing risk of death from non-AML causes, which is substantial in older MDS patients. Many patients, particularly in the Very Low and Low categories, will die of other causes before ever developing AML. The 25% figure therefore provides a more practically informative benchmark for counselling patients about leukaemic transformation risk during their expected lifetime.

Clinical Interpretation by Risk Category

Very Low Risk (Score ≤1.5)

Very Low risk IPSS-R patients have an expected median survival of 8.8 years, and the 25% AML cumulative incidence was not reached within the observation window of the derivation cohort. This survival approximates that of age-matched individuals without MDS in many epidemiological comparisons, reflecting the essentially smouldering biological character of this disease tier.

The primary management principle at this tier is watchful waiting combined with supportive care for symptomatic cytopenias. Disease-modifying therapy is not indicated in the absence of progressive or symptomatic cytopenia. Monitoring typically comprises full blood count every 3 to 6 months and repeat bone marrow assessment at clinically indicated intervals (evidence of count progression, new symptoms, or if the initial cytogenetic or blast data were suboptimal in quality).

For patients with transfusion-dependent anemia at this tier, erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin alfa are first-line where endogenous serum erythropoietin is low (commonly defined as <200 or <500 IU/L depending on local threshold) and transfusion burden is less than 2 units per month. The Nordic score (erythropoietin level and transfusion requirement) and the IWG 2023 criteria for ESA response guide treatment eligibility and response monitoring. Novel agents such as luspatercept (an erythroid maturation agent) have demonstrated efficacy in ring sideroblast- positive MDS and are now approved in this setting.

Low Risk (Score >1.5 to ≤3.0)

Low risk patients have a median survival of 5.3 years and a median time to 25% AML transformation of 10.8 years. As with Very Low risk, observation with supportive care is the primary strategy, but the higher cytopenia burden characteristic of this group means that active treatment of anemia, thrombocytopenia, or neutropenia is more frequently required.

Del(5q) MDS is a biologically and clinically important subcategory within this tier. Lenalidomide produces high rates of transfusion independence (approximately 67% at 24 weeks in the MDS-003 trial), cytogenetic remission, and durable responses in del(5q) MDS. Its mechanism involves targeted degradation of casein kinase 1α (CSNK1A1) encoded on the deleted chromosome 5q, restoring erythroid differentiation. Lenalidomide is not effective in non-del(5q) MDS at the same rates and is not indicated for higher-risk disease tiers as monotherapy.

Iron chelation therapy should be considered for transfusion-dependent Low risk patients who have received more than 20 to 25 units of packed red cells and have a serum ferritin consistently above 1,000 to 2,500 μg/L, as iron overload contributes to organ dysfunction independent of the underlying MDS. Oral deferasirox is the preferred agent in most patients given its convenience compared with subcutaneous deferoxamine.

Intermediate Risk (Score >3.0 to ≤4.5)

The Intermediate tier is the most clinically complex in the IPSS-R framework. With a median survival of 3.0 years and a median time to 25% AML transformation of 3.2 years, this group sits at a genuine biological and therapeutic inflection point. Patients may have features that align biologically with lower-risk disease (e.g. a patient with Intermediate cytogenetics, moderate anemia, and normal blasts) or with emerging higher-risk disease (e.g. a patient with borderline blast percentage and moderate- risk cytogenetics trending toward the High tier).

Treatment decisions in this tier require individualised assessment weighing:

• Symptom burden: Transfusion dependence, bleeding, infections, and constitutional symptoms (fatigue, weight loss, night sweats) that impair quality of life.
• Trajectory: Whether counts are stable, slowly worsening, or rapidly declining. Sequential IPSS-R assessments over 6 to 12 months can clarify trajectory.
• Transplant eligibility: Age, performance status, comorbidity index (the HCT-CI or the MDS-specific IPSS-R age-adjusted risk further refined by the IPSS-RA tool), and availability of a matched donor. Allogeneic stem cell transplantation is the only potentially curative treatment and should be discussed with all patients in this tier who are not clearly transplant-ineligible on the basis of age or comorbidities.
• Molecular genetics: Mutations such as TP53, RUNX1, ASXL1, and EZH2 carry adverse prognosis beyond IPSS-R score and may justify more aggressive treatment escalation even within the Intermediate tier.

Hypomethylating agents (HMAs), specifically azacitidine and decitabine, are the most commonly employed disease-modifying therapies for Intermediate risk MDS. They reactivate silenced tumour suppressor genes through inhibition of DNA methyltransferases, and produce complete remission in approximately 15 to 20% of patients. Overall response rates (complete plus partial response plus haematological improvement) range from 40 to 60% in clinical trial populations. Critically, azacitidine has been shown in the AZA-001 trial to prolong overall survival compared with conventional care regimens (including best supportive care, low-dose cytarabine, and standard chemotherapy) in higher-risk MDS patients, including the IPSS-R Intermediate group.

High Risk (Score >4.5 to ≤6.0)

High risk IPSS-R patients have a median survival of 1.6 years and a median time to 25% AML transformation of 1.4 years. The proximity of the AML transformation time to the overall survival median in this group underlines the urgency of treatment: a substantial proportion of these patients will either transform to AML before succumbing to non-leukaemic causes, or will die from complications of progressive bone marrow failure (infection, haemorrhage) in the absence of effective intervention.

Prompt initiation of treatment is a guiding principle in this tier. For patients who are not allogeneic transplant candidates (the majority, given the median age of this population and associated comorbidities), azacitidine remains the standard of care based on the survival benefit demonstrated in AZA-001. Decitabine is an alternative with comparable activity in uncontrolled comparisons. Oral formulations of both agents (oral azacitidine/cedazuridine and oral decitabine/cedazuridine as ASTX727) are now approved and offer patient convenience without established inferiority in terms of pharmacodynamic effect.

For eligible patients, allogeneic hematopoietic stem cell transplantation (alloHSCT) should be actively pursued. Transplant eligibility in MDS is influenced by age (no absolute upper limit in contemporary practice, but performance status and comorbidities become progressively more constraining above 70 to 75 years), comorbidity index, disease-specific factors (blast percentage at transplant, cytogenetics, molecular profile), and donor availability. Reduced-intensity conditioning regimens have extended alloHSCT eligibility to older and frailer patients. Relapsed or refractory disease post-HMA represents a major unmet need, with no globally approved second-line standard; clinical trial participation is strongly encouraged.

Very High Risk (Score >6.0)

Very High risk is the most adverse IPSS-R tier, with a median overall survival of approximately 0.8 years (9 to 10 months) and a median time to 25% AML transformation of 0.73 years (approximately 9 months). These patients are at immediate risk of life-threatening cytopenias and rapid disease progression and require urgent multidisciplinary evaluation.

Treatment should be initiated without delay. The clinical management principles are similar to those in the High risk tier but applied with greater urgency:

• HMA therapy should begin promptly if the patient is not proceeding directly to transplant conditioning.
• AlloHSCT should be pursued in all eligible patients. Pre-transplant cytoreduction with HMA or intensive induction-like chemotherapy (AML-type induction) may be considered to reduce blast burden before transplant, though the optimal pre-transplant strategy remains an area of active investigation.
• Goals-of-care discussions are essential. For patients who are not transplant candidates and in whom HMA therapy is unlikely to confer meaningful benefit (e.g. very elderly patients with multiple comorbidities and poor performance status), early integration of palliative and supportive care may better serve patient goals and quality of life than aggressive disease-modifying therapy.
• Clinical trial enrollment with novel agents (venetoclax combinations, IDH1/IDH2 inhibitors in mutated patients, magrolimab, sabatolimab, and others under investigation) should be strongly considered, as outcomes with currently approved treatments remain poor in this tier.

Age-Adjusted IPSS-R (IPSS-RA)

A practical limitation of the original IPSS-R is that it was derived from and applies to an untreated patient cohort with a wide age range, and the survival estimates therefore do not distinguish between the effects of MDS biology and the competing mortality of advanced age. Della Porta et al. proposed the age-adjusted IPSS-R (IPSS-RA), which modifies the score category by age decile to provide risk categories that are independent of age-related competing mortality. The IPSS-RA generates seven risk subgroups and can be particularly valuable when counselling younger patients (who are more likely to die of MDS than of competing causes) versus older patients (where competing mortality is substantial even in lower IPSS-R tiers).

Molecular IPSS (IPSS-M)

The most significant recent advance in MDS prognostication is the Molecular International Prognostic Scoring System (IPSS-M), published by Bernard et al. in NEJM Evidence in 2022. The IPSS-M was derived from a cohort of 2,957 MDS patients with comprehensive next-generation sequencing data alongside IPSS-R variables. It integrates 31 gene mutation features alongside the five IPSS-R clinical variables in a continuous hazard model that generates a patient-specific prognostic category on a finer scale than IPSS-R.

Key findings from the IPSS-M derivation and validation analyses include:

• Approximately 46% of patients are re-categorised into a different risk group when IPSS-M is used instead of IPSS-R, with the majority shifting from Intermediate or Low to a higher or lower category.
• Mutations in TP53 (biallelic), RUNX1, NRAS, FLT3, and PTPN11 are particularly adverse modifiers, while SF3B1 mutations confer a more favourable prognosis in the absence of other high-risk co-mutations.
• The IPSS-M is available as a web-based calculator (mds-risk-model.com) and is beginning to appear in international treatment guidelines as a recommended complement or successor to IPSS-R in centres with routine molecular diagnostics.

Importantly, the IPSS-M does not render IPSS-R obsolete. In settings where comprehensive molecular profiling is not routinely available, IPSS-R remains the practical and validated standard. Even where IPSS-M is calculated, IPSS-R provides a rapidly accessible, reproducible clinical anchor for urgent decisions (e.g. emergency admission, transfusion triage) while molecular results are pending.

IPSS-R in Relation to Other MDS Scoring Systems

Original IPSS (1997)

The original IPSS uses three cytogenetic groups (good, intermediate, poor), number of cytopenias (0, 1-2, or 3), and blast percentage (≤5%, 5-10%, 11-20%, 21-30%). It generates four risk categories (Low, INT-1, INT-2, High). The IPSS-R supersedes it in clinical practice due to finer cytogenetic granularity, individual rather than count-based cytopenia modelling, and the five-tier output with more clinically homogeneous groups. The IPSS is retained in some older clinical trials for historical comparisons and continues to be referenced in the treatment guidelines it shaped.

WHO Classification-Based Prognostic Scoring System (WPSS)

The WPSS, published by Malcovati et al. in 2007, incorporates WHO morphological subtype, cytogenetic risk (IPSS three groups), and transfusion dependency (regular transfusions defined as at least one unit per 8 weeks over 4 months). Its advantage over IPSS is explicit inclusion of transfusion burden as a prognostic variable, since transfusion dependency is both a marker of disease severity and an independent prognostic factor beyond what is captured by cytopenia values alone. The WPSS is dynamic: it can be recalculated at follow-up visits to capture disease progression, making it useful for monitoring trajectory over time. It is less widely used in current practice than IPSS-R but remains relevant in institutions with strong WHO morphological classification traditions.

MDS-CI (Comorbidity Index)

The MDS-Comorbidity Index (MDS-CI), developed by Della Porta et al., scores the presence of cardiac disease, moderate/severe hepatic impairment, renal disease, solid tumour, and pulmonary disease to provide a comorbidity adjustment to MDS prognosis. Its primary utility is in transplant candidacy assessment, where IPSS-R-defined disease risk must be weighed against treatment-related mortality risk from alloHSCT. The MDS-CI complements rather than competes with IPSS-R.

Practical Considerations for Score Calculation

Timing and Context of Assessment

The IPSS-R was derived from values obtained at the time of initial diagnosis in untreated patients. For accurate and guideline-appropriate prognostication, scores should be calculated using pre-treatment values from the diagnostic bone marrow assessment. Calculating IPSS-R after transfusion, growth factor administration, or disease-modifying therapy will yield values that do not correspond to the validated outcome benchmarks.

In practice, repeat scoring at disease reassessment points (e.g. after HMA induction cycles, at the time of relapse, or at clinical deterioration) provides longitudinal prognostic information and helps identify patients who have transitioned to a higher risk tier, warranting treatment escalation. Sequential IPSS-R scores function as a dynamic risk tracking tool in this context, though their formal validation is primarily in the diagnostic setting.

Cytogenetic Report Interpretation

Assigning the correct IPSS-R cytogenetic group requires careful reading of the karyotype report. Key distinctions include:

• Monosomy 7 (−7) is Poor, while del(7q) (partial long-arm deletion of chromosome 7) is Intermediate — a clinically important distinction with direct prognostic and treatment implications.
• Complex karyotype with exactly 3 abnormalities is Poor, while more than 3 abnormalities constitute Very Poor. Counting the number of distinct chromosomal abnormalities rather than the number of abnormal clones is the correct approach.
• del(5q) as a sole abnormality or combined with one other non-adverse change is Good. When del(5q) co-occurs with −7 or complex changes, the karyotype is re-classified according to the composite abnormalities.
• When metaphase cytogenetics yield no informative metaphases or insufficient data (fewer than 20 analysed), the karyotypic risk group may be considered Good (normal by inference) but this assumption should be documented and FISH or alternative methodology pursued. Do not assign a favourable cytogenetic group in the absence of confirmatory data in high-risk clinical settings.

Peripheral Blood Values

The hemoglobin, platelet count, and ANC for IPSS-R scoring should be taken from the diagnostic complete blood count closest in time to the bone marrow assessment, prior to any disease-modifying or growth-factor intervention. If the patient has received a recent transfusion or administration of granulocyte colony-stimulating factor (G-CSF), the pre-intervention values should be used where retrievable from the medical record. If only post-intervention values are available, this limitation should be noted in the clinical documentation.

Special Populations

Younger Adults with MDS

MDS in patients below 50 years of age is uncommon (accounting for fewer than 5% of all MDS cases) but raises distinct diagnostic and management considerations. In younger patients, it is essential to exclude inherited bone marrow failure syndromes (Fanconi anaemia, Shwachman-Diamond syndrome, Diamond-Blackfan anaemia, dyskeratosis congenita) that may present with or evolve to MDS. Germline mutation testing (particularly RUNX1, GATA2, DDX41, ANKRD26) should be considered. IPSS-R prognosis in younger adults is generally more favourable than the age-standardised estimates suggest, as competing mortality from non-MDS causes is lower. AlloHSCT is more readily accessible and should be pursued aggressively in higher-risk young patients.

Therapy-Related MDS (t-MDS)

MDS arising after prior cytotoxic chemotherapy or radiotherapy (therapy-related MDS) is excluded from the IPSS-R derivation cohort. t-MDS has systematically worse outcomes than primary MDS at equivalent IPSS-R scores, due to germline and acquired DNA repair deficiencies, higher frequencies of adverse cytogenetics (including complex karyotype with TP53 mutation), and impaired bone marrow reserve from prior treatment. The IPSS-R score provides useful prognostic structuring in t-MDS but should be interpreted with the knowledge that absolute survival estimates are likely to be lower than the primary MDS benchmarks.

MDS with SF3B1 Mutation

Mutations in SF3B1, which encode a core spliceosome component, are present in approximately 25 to 30% of MDS patients and are strongly associated with ring sideroblasts and a more indolent clinical course. The 2022 WHO classification recognises MDS with SF3B1 mutation as a distinct entity. In the IPSS-M, SF3B1 mutation confers a favourable modifier that can downgrade patients from IPSS-R Intermediate to IPSS-M Low risk. SF3B1-mutated patients are also the primary population with documented benefit from luspatercept, which is now approved for ESA-refractory or ESA-ineligible anemia in this subgroup.

MDS with TP53 Mutation

TP53 mutations occur in approximately 5 to 10% of MDS patients overall but in 30 to 40% of those with complex karyotype or Very Poor cytogenetics. Biallelic TP53 inactivation (either two distinct mutations or a mutation plus allelic deletion) confers extremely poor prognosis, with median survival often below 6 to 12 months regardless of IPSS-R tier. AlloHSCT outcomes are also poor, with high relapse rates, though transplant may still offer the best chance of long-term disease control in selected patients. Novel agents targeting TP53-mutant clones (APR-246/eprenetapopt, magrolimab, tamibarotene) are under active investigation.

Limitations of the IPSS-R

• Derivation in untreated primary MDS only: The score is not validated for therapy-related MDS, secondary MDS from myeloproliferative neoplasms (MDS/MPN overlap), or post-treatment disease. Application in these settings yields prognostic estimates that may not accurately reflect patient outcomes.
• No molecular genetic variables: The IPSS-R predates the routine availability of next-generation sequencing in MDS diagnostics. It does not capture the independent prognostic weight of somatic mutations in genes such as TP53, RUNX1, ASXL1, EZH2, SF3B1, and others. The IPSS-M addresses this gap for centres with molecular profiling capability.
• Age as a competing risk: The IPSS-R outcome estimates reflect the composite of MDS-specific mortality and competing non-MDS mortality in a mixed-age cohort. Older patients may have IPSS-R-derived survival estimates that overestimate MDS-attributable risk, while younger patients may be underestimated. The IPSS-RA (age-adjusted IPSS-R) is a tool to address this.
• Intermediate tier heterogeneity: The Intermediate risk category spans a score range (3 to 4.5) that encompasses biologically diverse patients. Outcomes within this tier vary substantially, and the score does not reliably distinguish patients who will behave more like Low-risk from those who will behave more like High-risk MDS.
• Single time-point assessment: Like all static prognostic scores, IPSS-R does not capture disease trajectory. A patient with rapidly declining counts and a currently Intermediate score may have a worse near-term prognosis than a patient with stable Intermediate scores over two years. Serial assessment with attention to count trends supplements the static score.
• Cytogenetic failure rate: Bone marrow cytogenetics may fail to yield informative metaphases in up to 10 to 15% of MDS cases, particularly in hypocellular specimens. This introduces uncertainty in cytogenetic risk group assignment. Where FISH or chromosomal microarray is performed, the results should inform cytogenetic risk classification using clinical judgement in the absence of formal validation of these modalities within the IPSS-R framework.

How to Use This Calculator

The CalcMD IPSS-R calculator requires five inputs, all of which should be obtained from the diagnostic workup:

1. Cytogenetic risk group: Select the category (Very Good, Good, Intermediate, Poor, or Very Poor) that best matches the bone marrow karyotype report, using the specific karyotype descriptors listed for each group. When in doubt, refer to the Greenberg 2012 Blood manuscript supplementary tables for the complete list of assigned karyotypes.
2. Bone marrow blasts (%): Enter the blast percentage as reported on the bone marrow aspirate differential. Use CT-corrected or flow cytometry-adjusted values where available and documented. Note that IPSS-R applies to patients with blasts below 20%; a result of 20% or above indicates AML and IPSS-R does not apply.
3. Hemoglobin (g/dL): Enter the pre-treatment, pre-transfusion value from the diagnostic CBC. Use the most recent pre-transfusion value if chronic transfusion support is ongoing.
4. Platelet count (×10⁹/L): Enter the platelet count from the diagnostic CBC, ideally from the same sample as hemoglobin.
5. Absolute neutrophil count (ANC, ×10⁹/L): Enter the ANC. If not directly reported, calculate as: total white cell count × (% neutrophils + % bands) ÷ 100.

The calculator will display the total IPSS-R score, the individual subscore contribution from each variable, the risk category, and the associated median overall survival and time-to-25%-AML-transformation benchmarks from the Greenberg 2012 derivation cohort. These values are intended to support clinical communication and treatment planning and should not be used in isolation to determine individual patient management.